Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 610

1.

Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC.

Klempner SJ, Hata AN.

J Thorac Oncol. 2019 Nov;14(11):1875-1877. doi: 10.1016/j.jtho.2019.07.014. No abstract available.

PMID:
31668312
2.

Deciphering the Role of Eosinophils in Solid Organ Transplantation.

Onyema OO, Guo Y, Hata A, Kreisel D, Gelman AE, Jacobsen EA, Krupnick AS.

Am J Transplant. 2019 Oct 24. doi: 10.1111/ajt.15660. [Epub ahead of print] Review.

PMID:
31647606
3.

Successful Conservative Treatment of Mycotic Pulmonary Artery Aneurysms Caused by MRSA Bacteremia.

Iki Y, Hata A, Fukuyama M, Yoshioka T, Watanabe K, Asari S, Hata D.

Pediatrics. 2019 Nov;144(5). pii: e20190672. doi: 10.1542/peds.2019-0672. Epub 2019 Oct 17.

PMID:
31624217
4.

Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.

Fujimoto J, Kurasawa O, Takagi T, Liu X, Banno H, Kojima T, Asano Y, Nakamura A, Nambu T, Hata A, Ishii T, Sameshima T, Debori Y, Miyamoto M, Klein MG, Tjhen R, Sang BC, Levin I, Lane SW, Snell GP, Li K, Kefala G, Hoffman ID, Ding SC, Cary DR, Mizojiri R.

ACS Med Chem Lett. 2019 Sep 19;10(10):1498-1503. doi: 10.1021/acsmedchemlett.9b00400. eCollection 2019 Oct 10.

PMID:
31620240
5.

Reference values of hematological and blood biochemical parameters for the Noma horse.

Ono T, Yamada Y, Hata A, Shimokawa Miyama T, Shibano K, Iwata E, Ohzawa E, Kitagawa H.

J Equine Sci. 2019 Sep;30(3):69-73. doi: 10.1294/jes.30.69. Epub 2019 Oct 2.

6.

Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.

Dagogo-Jack I, Piotrowska Z, Cobb R, Banwait M, Lennerz JK, Hata AN, Digumarthy SR, Sequist LV.

J Thorac Oncol. 2019 Oct;14(10):e226-e228. doi: 10.1016/j.jtho.2019.05.046. No abstract available.

PMID:
31558234
7.

A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Tachihara M, Kiriu T, Hata A, Hatakeyama Y, Nakata K, Nagano T, Yamamoto M, Kobayashi K, Ohnishi H, Katakami N, Nishimura Y.

Cancer Manag Res. 2019 Jul 29;11:7135-7140. doi: 10.2147/CMAR.S208224. eCollection 2019.

8.

Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation.

Niu J, Sun Y, Chen B, Zheng B, Jarugumilli GK, Walker SR, Hata AN, Mino-Kenudson M, Frank DA, Wu X.

Nature. 2019 Sep;573(7772):139-143. doi: 10.1038/s41586-019-1511-x. Epub 2019 Aug 28.

PMID:
31462771
9.

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.

Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, Digumarthy SR, Sequist LV, Hata AN, Maheswaran S, Haber DA, Lawrence MS, Shaw AT, Mino-Kenudson M, Dyson NJ, Drapkin BJ.

Cancer Discov. 2019 Oct;9(10):1372-1387. doi: 10.1158/2159-8290.CD-19-0582. Epub 2019 Aug 15.

PMID:
31416802
10.

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-Hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata AN, Shaw AT, Nishio M, Fujita N, Isoyama T.

Nat Commun. 2019 Aug 9;10(1):3604. doi: 10.1038/s41467-019-11496-z.

11.

Diffuse hair loss following anti-programmed cell death-1 antibody treatment: a case report with immunohistochemical analysis.

Komatsu-Fujii T, Otsuka A, Ishida Y, Kaku Y, Yamashita C, Hata A, Kataoka T, Honda T, Kabashima K.

Eur J Dermatol. 2019 Jun 1;29(3):326-327. doi: 10.1684/ejd.2019.3547. No abstract available.

PMID:
31389791
12.

Metabolism of 3-[5'-deoxy-5'-(dimethylarsinoyl)-β-ribofuranosyloxy]-2-hydroxypropylene glycol in an artificial digestive system.

Hata A, Hasegawa M, Yamauchi T, Otomo Y, Miura M, Yamanaka K, Yamano Y, Fujitani N, Endo G.

Heliyon. 2019 Jul 19;5(7):e02079. doi: 10.1016/j.heliyon.2019.e02079. eCollection 2019 Jul.

13.

Correction to: Investigation of novel variations of ORAI1 gene and their association with Kawasaki disease.

Thiha K, Mashimo Y, Suzuki H, Hamada H, Hata A, Hara T, Tanaka T, Ito K, Onouchi Y; Japan Kawasaki Disease Genome Consortium.

J Hum Genet. 2019 Oct;64(10):1049. doi: 10.1038/s10038-019-0645-x.

PMID:
31366996
14.

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.

Dagogo-Jack I, Rooney M, Lin JJ, Nagy RJ, Yeap BY, Hubbeling H, Chin E, Ackil J, Farago AF, Hata AN, Lennerz JK, Gainor JF, Lanman RB, Shaw AT.

Clin Cancer Res. 2019 Jul 29. doi: 10.1158/1078-0432.CCR-19-1436. [Epub ahead of print]

PMID:
31358542
15.

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.

Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, Hafeez N, Bilton SJ, Drier Y, Ji F, Greenberg M, Williams A, Kattermann K, Damon L, Sovath S, Rakiec DP, Korn JM, Ruddy DA, Benes CH, Hammerman PS, Piotrowska Z, Sequist LV, Niederst MJ, Barretina J, Engelman JA, Hata AN.

Oncogene. 2019 Sep;38(37):6399-6413. doi: 10.1038/s41388-019-0887-2. Epub 2019 Jul 19.

PMID:
31324888
16.

A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis.

Hata A, Nakajima T, Matsusaka K, Fukuyo M, Morimoto J, Yamamoto T, Sakairi Y, Rahmutulla B, Ota S, Wada H, Suzuki H, Matsubara H, Yoshino I, Kaneda A.

Int J Cancer. 2019 Jun 26. doi: 10.1002/ijc.32532. [Epub ahead of print]

PMID:
31241180
17.

Application of deep learning (3-dimensional convolutional neural network) for the prediction of pathological invasiveness in lung adenocarcinoma: A preliminary study.

Yanagawa M, Niioka H, Hata A, Kikuchi N, Honda O, Kurakami H, Morii E, Noguchi M, Watanabe Y, Miyake J, Tomiyama N.

Medicine (Baltimore). 2019 Jun;98(25):e16119. doi: 10.1097/MD.0000000000016119.

18.

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.

Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H.

Cell Rep. 2019 Jun 18;27(12):3422-3432.e4. doi: 10.1016/j.celrep.2019.05.058.

19.

Handheld flow meter improves COPD detectability regardless of using a conventional questionnaire: A split-sample validation study.

Fujita M, Nagashima K, Takahashi S, Suzuki K, Fujisawa T, Hata A.

Respirology. 2019 Jun 12. doi: 10.1111/resp.13602. [Epub ahead of print]

PMID:
31188538
20.

Ultra-low-dose chest computed tomography for interstitial lung disease using model-based iterative reconstruction with or without the lung setting.

Hata A, Yanagawa M, Honda O, Miyata T, Tomiyama N.

Medicine (Baltimore). 2019 May;98(22):e15936. doi: 10.1097/MD.0000000000015936.

21.

Maslinic acid derived from olive fruit in combination with resistance training improves muscle mass and mobility functions in the elderly.

Nagai N, Yagyu S, Hata A, Nirengi S, Kotani K, Moritani T, Sakane N.

J Clin Biochem Nutr. 2019 May;64(3):224-230. doi: 10.3164/jcbn.18-104. Epub 2019 Mar 7.

22.

Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.

Grassberger C, McClatchy D 3rd, Geng C, Kamran SC, Fintelmann F, Maruvka YE, Piotrowska Z, Willers H, Sequist LV, Hata AN, Paganetti H.

Cancer Res. 2019 Jul 15;79(14):3776-3788. doi: 10.1158/0008-5472.CAN-18-3652. Epub 2019 May 21.

PMID:
31113818
23.

Chronological changes of skin eruptions in an infantile case of annular pustular psoriasis.

Hata A, Egawa G, Nomura T, Kabashima K.

J Dermatol. 2019 Oct;46(10):e372-e373. doi: 10.1111/1346-8138.14929. Epub 2019 May 20. No abstract available.

PMID:
31106884
24.

Development of an LC-MS/MS-based method for quantitation of osimertinib in human plasma and cerebrospinal fluid.

Irie K, Nanjo S, Hata A, Yamasaki Y, Okada Y, Katakami N, Fukushima S.

Bioanalysis. 2019 May;11(9):847-854. doi: 10.4155/bio-2018-0292. Epub 2019 May 14.

PMID:
31084202
25.

Myelodysplastic Syndrome-Associated SRSF2 Mutations Cause Splicing Changes by Altering Binding Motif Sequences.

Masaki S, Ikeda S, Hata A, Shiozawa Y, Kon A, Ogawa S, Suzuki K, Hakuno F, Takahashi SI, Kataoka N.

Front Genet. 2019 Apr 16;10:338. doi: 10.3389/fgene.2019.00338. eCollection 2019.

26.

Molecular cytogenetic characterization of repetitive sequences comprising centromeric heterochromatin in three Anseriformes species.

Uno Y, Nishida C, Hata A, Ishishita S, Matsuda Y.

PLoS One. 2019 Mar 26;14(3):e0214028. doi: 10.1371/journal.pone.0214028. eCollection 2019.

27.

Inequality within a community at the neighborhood level and the incidence of mood disorders in Japan: a multilevel analysis.

Fujita M, Nagashima K, Takahashi S, Hata A.

Soc Psychiatry Psychiatr Epidemiol. 2019 Sep;54(9):1125-1131. doi: 10.1007/s00127-019-01687-w. Epub 2019 Mar 22.

PMID:
30903241
28.

Deregulation of Drosha in the pathogenesis of hereditary hemorrhagic telangiectasia.

Hata A, Lagna G.

Curr Opin Hematol. 2019 May;26(3):161-169. doi: 10.1097/MOH.0000000000000493.

29.

Investigation of novel variations of ORAI1 gene and their association with Kawasaki disease.

Thiha K, Mashimo Y, Suzuki H, Hamada H, Hata A, Hara T, Tanaka T, Ito K, Onouchi Y; Japan Kawasaki Disease Genome Consortium.

J Hum Genet. 2019 Jun;64(6):511-519. doi: 10.1038/s10038-019-0588-2. Epub 2019 Mar 11. Erratum in: J Hum Genet. 2019 Oct;64(10):1049.

PMID:
30853710
30.

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.

Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators.

Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Erratum in: Lancet. 2019 Mar 30;393(10178):1298. Lancet. 2019 Apr 13;393(10180):1504.

PMID:
30853151
31.

Association between blood manganese level during pregnancy and birth size: The Japan environment and children's study (JECS).

Yamamoto M, Sakurai K, Eguchi A, Yamazaki S, Nakayama SF, Isobe T, Takeuchi A, Sato T, Hata A, Mori C, Nitta H; Japan Environment and Children's Study Group:.

Environ Res. 2019 May;172:117-126. doi: 10.1016/j.envres.2019.02.007. Epub 2019 Feb 8.

32.

Precise Anatomical Sublobar Resection Using a 3D Medical Image Analyzer and Fluorescence-Guided Surgery With Transbronchial Instillation of Indocyanine Green.

Sekine Y, Itoh T, Toyoda T, Kaiho T, Koh E, Kamata T, Hoshino H, Hata A.

Semin Thorac Cardiovasc Surg. 2019 Autumn;31(3):595-602. doi: 10.1053/j.semtcvs.2019.01.004. Epub 2019 Jan 5.

PMID:
30616007
33.
34.

Volumetric analysis of the thymic epithelial tumors: correlation of tumor volume with the WHO classification and Masaoka staging.

Sato Y, Yanagawa M, Hata A, Enchi Y, Kikuchi N, Honda O, Nakanishi K, Tomiyama N.

J Thorac Dis. 2018 Oct;10(10):5822-5832. doi: 10.21037/jtd.2018.09.133. Erratum in: J Thorac Dis. 2019 May;11(5):E79.

35.

Soy product and isoflavone intake associations with allergic diseases in Japanese workers: rhinitis, dermatitis and asthma.

Nakamoto M, Shuto E, Nakamoto A, Hata A, Aki N, Shikama Y, Bando Y, Ichihara T, Minagawa T, Tamura A, Kuwamura Y, Funaki M, Sakai T.

Asia Pac J Clin Nutr. 2018;27(6):1277-1285. doi: 10.6133/apjcn.201811_27(6).0015.

36.

Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S; HANSHIN Oncology Group.

Oncotarget. 2018 Oct 5;9(78):34765-34771. doi: 10.18632/oncotarget.26192. eCollection 2018 Oct 5.

37.

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.

Misale S, Fatherree JP, Cortez E, Li C, Bilton S, Timonina D, Myers DT, Lee D, Gomez-Caraballo M, Greenberg M, Nangia V, Greninger P, Egan RK, McClanaghan J, Stein GT, Murchie E, Zarrinkar PP, Janes MR, Li LS, Liu Y, Hata AN, Benes CH.

Clin Cancer Res. 2019 Jan 15;25(2):796-807. doi: 10.1158/1078-0432.CCR-18-0368. Epub 2018 Oct 16.

PMID:
30327306
38.

Chronological changes in epidemiological characteristics of lower urinary tract urolithiasis in Japan.

Sakamoto S, Miyazawa K, Yasui T, Iguchi T, Fujita M, Nishimatsu H, Masaki T, Hasegawa T, Hibi H, Arakawa T, Ando R, Kato Y, Ishito N, Yamaguchi S, Takazawa R, Tsujihata M, Taguchi M, Akakura K, Hata A, Ichikawa T.

Int J Urol. 2019 Jan;26(1):96-101. doi: 10.1111/iju.13817. Epub 2018 Oct 11.

PMID:
30308705
39.

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).

Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S.

BMC Cancer. 2018 Oct 3;18(1):946. doi: 10.1186/s12885-018-4819-2.

40.

Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells.

Vattulainen-Collanus S, Southwood M, Yang XD, Moore S, Ghatpande P, Morrell NW, Lagna G, Hata A.

Commun Biol. 2018 Sep 24;1:149. doi: 10.1038/s42003-018-0152-1. eCollection 2018.

41.

Differences in apoptotic signaling and toxicity between dimethylmonothioarsinic acid (DMMTAV) and its active metabolite, dimethylarsinous acid (DMAIII), in HepaRG cells: Possibility of apoptosis cascade based on diversity of active metabolites of DMMTAV.

Shimoda Y, Kato K, Asami S, Kurita M, Kurosawa H, Toriyama M, Miura M, Hata A, Endo Y, Endo G, An Y, Yamanaka K.

J Trace Elem Med Biol. 2018 Dec;50:188-197. doi: 10.1016/j.jtemb.2018.07.003. Epub 2018 Jul 10.

PMID:
30262279
42.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV.

Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26.

PMID:
30257958
43.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN.

Cancer Discov. 2018 Dec;8(12):1598-1613. doi: 10.1158/2159-8290.CD-18-0277. Epub 2018 Sep 25.

PMID:
30254092
44.
45.

Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study.

Akamatsu H, Koh Y, Ozawa Y, Fujimoto D, Hata A, Katakami N, Tomii K, Shimokawa T, Yamamoto N.

Clin Lung Cancer. 2018 Nov;19(6):e871-e874. doi: 10.1016/j.cllc.2018.08.001. Epub 2018 Aug 22.

46.

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S, The Hanshin Oncology Group F.

Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7.

47.

Comprehensive Study on Enteric Viruses and Indicators in Surface Water in Kyoto, Japan, During 2014-2015 Season.

Hata A, Hanamoto S, Ihara M, Shirasaka Y, Yamashita N, Tanaka H.

Food Environ Virol. 2018 Dec;10(4):353-364. doi: 10.1007/s12560-018-9355-3. Epub 2018 Aug 27.

PMID:
30151619
48.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, Moody S, Niederst MJ, Engelman JA, Hata AN, Corcoran RB, Sequist LV.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00263. Epub 2018 Jul 16.

49.

Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.

Yoda S, Dagogo-Jack I, Hata AN.

Pharmacol Ther. 2019 Jan;193:20-30. doi: 10.1016/j.pharmthera.2018.08.007. Epub 2018 Aug 16. Review.

PMID:
30121320
50.

Next-generation amplicon sequencing identifies genetically diverse human astroviruses, including recombinant strains, in environmental waters.

Hata A, Kitajima M, Haramoto E, Lee S, Ihara M, Gerba CP, Tanaka H.

Sci Rep. 2018 Aug 7;8(1):11837. doi: 10.1038/s41598-018-30217-y.

Supplemental Content

Support Center